1196059-70-7 Usage
Explanation
The molecular formula represents the number of atoms of each element present in a molecule. In this case, the compound has 19 carbon (C) atoms, 14 hydrogen (H) atoms, 4 nitrogen (N) atoms, and 1 oxygen (O) atom.
Explanation
Heterocyclic compounds are organic compounds containing a ring of atoms with at least one heteroatom (an atom other than carbon). In this case, the compound contains nitrogen (N) and oxygen (O) as heteroatoms.
Explanation
The compound is of interest in medicinal chemistry due to its potential pharmaceutical properties. It may be used in the development of drugs targeting specific biological processes or pathways.
Explanation
Further research and evaluation of this compound may lead to the discovery of new therapeutic agents for various medical conditions. Its unique structure and properties make it a promising candidate for drug development.
Explanation
The compound's potential pharmaceutical properties make it a candidate for targeting specific biological processes or pathways. This could lead to the development of drugs that are more effective and have fewer side effects.
Explanation
To fully understand the compound's potential as a therapeutic agent, further research and evaluation are required. This may include studying its interactions with biological targets, assessing its pharmacokinetics, and evaluating its safety and efficacy in preclinical and clinical trials.
Structure
Benzimidazole ring connected to a carboxamide group and a phenyl ring with a pyridinyl group
Chemical Class
Heterocyclic compound
Application
Medicinal chemistry
Potential Use
Development of therapeutic agents
Research Focus
Targeting specific biological processes or pathways
Further Evaluation
Additional research needed
Check Digit Verification of cas no
The CAS Registry Mumber 1196059-70-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,6,0,5 and 9 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1196059-70:
(9*1)+(8*1)+(7*9)+(6*6)+(5*0)+(4*5)+(3*9)+(2*7)+(1*0)=177
177 % 10 = 7
So 1196059-70-7 is a valid CAS Registry Number.
1196059-70-7Relevant articles and documents
Benzimidazole derivatives as potential dual inhibitors for PARP-1 and DHODH
Abdullah, Iskandar,Chee, Chin Fei,Lee, Yean-Kee,Thunuguntla, Siva Sanjeeva Rao,Satish Reddy,Nellore, Kavitha,Antony, Thomas,Verma, Jitender,Mun, Kong Wai,Othman, Shatrah,Subramanya, Hosahalli,Rahman, Noorsaadah Abd.
, p. 4669 - 4680 (2015/08/03)
Poly (ADP-ribose) polymerases (PARPs) play diverse roles in various cellular processes that involve DNA repair and programmed cell death. Amongst these polymerases is PARP-1 which is the key DNA damage-sensing enzyme that acts as an initiator for the DNA
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents
Tong, Yunsong,Bouska, Jennifer J.,Ellis, Paul A.,Johnson, Eric F.,Leverson, Joel,Liu, Xuesong,Marcotte, Patrick A.,Olson, Amanda M.,Osterling, Donald J.,Przytulinska, Magdalena,Rodriguez, Luis E.,Shi, Yan,Soni, Nirupama,Stavropoulos, Jason,Thomas, Sheela,Donawho, Cherrie K.,Frost, David J.,Luo, Yan,Giranda, Vincent L.,Penning, Thomas D.
experimental part, p. 6803 - 6813 (2010/04/06)
Small molecule inhibitors of PARP-1 have been pursued by various organizations as potential therapeutic agents either capable of sensitizing cytotoxic treatments or acting as stand-alone agents to combat cancer. As one of the strategies to expand our portfolio of PARP-1 inhibitors, we pursued unsaturated heterocycles to replace the saturated cyclic amine derivatives appended to the benzimidazole core. Not only did a variety of these new generation compounds maintain high enzymatic potency, many of them also displayed robust cellular activity. For example, the enzymatic IC50 and cellular EC50 values were as low as 1 nM or below. Compounds 24 (EC50 = 3.7 nM) and 44 (EC50 = 7.8 nM), featuring an oxadiazole and a pyridine moiety, respectively, demonstrated balanced potency and PK profiles. In addition, these two molecules exhibited potent oral in vivo efficacy in potentiating the cytotoxic agent temozolomide in a B16F10 murine melanoma model.
